BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

Drug testing program targets transportation industry

Drug testing program targets transportation industry

ProSight Specialty Insurance said Monday that it has partnered with transportation compliance firm, Hartford, Connecticut-based Foley Carrier Services L.L.C. to launch ProSight's Drug Testing Program.

ProSight's Drug Testing Program is an enhanced drug test that goes beyond standard Department of Transportation-compliant testing to identify the riskiest drivers that typically go undetected by. It was created to raise safety standards in the transportation industry, Morristown, New Jersey-based ProSight Specialty Insurance said in a statement. The basic panel test includes Marijuana, Cocaine, Basic Opiates, Amphetamines and PCP. The enhanced test is designed to pick up more modern drugs that are not captured in the DOT drug test these include Benzodiazepines, Barbiturates, Expanded opiates (synthetic morphine, oxycodone), Synthetic marijuana and Ecstasy, according to a ProSight Specialty Insurance spokeswoman.

“ProSight is fully committed to working with industry experts to solve problems that affect our transportation customers,” Jeremy Zottneck, president for transportation niche at ProSight said in the statement. “We're very excited to partner with Foley to offer an enhanced drug test that will help customers boost their productivity, reduce driver churn, decrease dangerous incidents and improve overall ROI.”

Read Next

  • Employers testing new ways to rein in specialty drug costs

    PALM SPRINGS, Calif. — To rein in rising specialty drug costs, employers most often use prior authorization, step therapy and cost-sharing strategies, but more are also experimenting with formulary exclusions and value-based pricing models, a new report shows.